View in EDS

Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial.

Saved in:
Bibliographic Details
Title: Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial.
Authors: Wainberg ZA; Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA. zwainberg@mednet.ucla.edu.; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA. zwainberg@mednet.ucla.edu.; Department of Surgery, University of California Los Angeles, Los Angeles, CA, USA. zwainberg@mednet.ucla.edu., Link JM; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA. jmlink@mednet.ucla.edu.; Department of Surgery, University of California Los Angeles, Los Angeles, CA, USA. jmlink@mednet.ucla.edu., Premji A; Department of Surgery, University of California Los Angeles, Los Angeles, CA, USA., Zheng S; Department of Surgery, University of California Los Angeles, Los Angeles, CA, USA., Srienc M; Department of Surgery, University of California Los Angeles, Los Angeles, CA, USA., Hammons M; David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA., Kim SE; David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA., Li L; Department of Surgery, University of California Los Angeles, Los Angeles, CA, USA., Liu Z; David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA., Tsvetkova O; David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA., Abt ER; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.; Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA., Rosen L; Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA., Kim S; Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA., King J; Department of Surgery, University of California Los Angeles, Los Angeles, CA, USA., Hines OJ; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.; Department of Surgery, University of California Los Angeles, Los Angeles, CA, USA., Girgis M; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.; Department of Surgery, University of California Los Angeles, Los Angeles, CA, USA., Sadeghi S; Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA., Olevsky O; Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA., Wong D; Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA., Yonemoto L; Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA., Siney AM; Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA., Kelly K; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA., Kivork C; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA., Tseng CH; Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA., Radu CG; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.; Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA., Dawson DW; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.; Department of Pathology and Laboratory Medicine, University of California, Los Angeles, CA, USA., Donahue TR; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA. tdonahue@mednet.ucla.edu.; Department of Surgery, University of California Los Angeles, Los Angeles, CA, USA. tdonahue@mednet.ucla.edu.; Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA. tdonahue@mednet.ucla.edu.
Source: Nature communications [Nat Commun] 2026 Jan 31; Vol. 17 (1). Date of Electronic Publication: 2026 Jan 31.
Publication Type: Clinical Trial, Phase I; Journal Article
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41620440
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Wainberg+ZA%22">Wainberg ZA</searchLink>; Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA. zwainberg@mednet.ucla.edu.; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA. zwainberg@mednet.ucla.edu.; Department of Surgery, University of California Los Angeles, Los Angeles, CA, USA. zwainberg@mednet.ucla.edu.<br /><searchLink fieldCode="AU" term="%22Link+JM%22">Link JM</searchLink>; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA. jmlink@mednet.ucla.edu.; Department of Surgery, University of California Los Angeles, Los Angeles, CA, USA. jmlink@mednet.ucla.edu.<br /><searchLink fieldCode="AU" term="%22Premji+A%22">Premji A</searchLink>; Department of Surgery, University of California Los Angeles, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Zheng+S%22">Zheng S</searchLink>; Department of Surgery, University of California Los Angeles, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Srienc+M%22">Srienc M</searchLink>; Department of Surgery, University of California Los Angeles, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Hammons+M%22">Hammons M</searchLink>; David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Kim+SE%22">Kim SE</searchLink>; David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Li+L%22">Li L</searchLink>; Department of Surgery, University of California Los Angeles, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Liu+Z%22">Liu Z</searchLink>; David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Tsvetkova+O%22">Tsvetkova O</searchLink>; David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Abt+ER%22">Abt ER</searchLink>; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.; Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Rosen+L%22">Rosen L</searchLink>; Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Kim+S%22">Kim S</searchLink>; Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22King+J%22">King J</searchLink>; Department of Surgery, University of California Los Angeles, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Hines+OJ%22">Hines OJ</searchLink>; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.; Department of Surgery, University of California Los Angeles, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Girgis+M%22">Girgis M</searchLink>; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.; Department of Surgery, University of California Los Angeles, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Sadeghi+S%22">Sadeghi S</searchLink>; Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Olevsky+O%22">Olevsky O</searchLink>; Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Wong+D%22">Wong D</searchLink>; Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Yonemoto+L%22">Yonemoto L</searchLink>; Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Siney+AM%22">Siney AM</searchLink>; Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Kelly+K%22">Kelly K</searchLink>; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Kivork+C%22">Kivork C</searchLink>; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Tseng+CH%22">Tseng CH</searchLink>; Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Radu+CG%22">Radu CG</searchLink>; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.; Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Dawson+DW%22">Dawson DW</searchLink>; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.; Department of Pathology and Laboratory Medicine, University of California, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Donahue+TR%22">Donahue TR</searchLink>; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA. tdonahue@mednet.ucla.edu.; Department of Surgery, University of California Los Angeles, Los Angeles, CA, USA. tdonahue@mednet.ucla.edu.; Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA. tdonahue@mednet.ucla.edu.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101528555%22">Nature communications</searchLink> [Nat Commun] 2026 Jan 31; Vol. 17 (1). <i>Date of Electronic Publication: </i>2026 Jan 31.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101528555 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2041-1723 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220411723%22">20411723 </searchLink><i>NLM ISO Abbreviation: </i>Nat Commun <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41620440
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41467-026-68976-2
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Wainberg ZA
      – PersonEntity:
          Name:
            NameFull: Link JM
      – PersonEntity:
          Name:
            NameFull: Premji A
      – PersonEntity:
          Name:
            NameFull: Zheng S
      – PersonEntity:
          Name:
            NameFull: Srienc M
      – PersonEntity:
          Name:
            NameFull: Hammons M
      – PersonEntity:
          Name:
            NameFull: Kim SE
      – PersonEntity:
          Name:
            NameFull: Li L
      – PersonEntity:
          Name:
            NameFull: Liu Z
      – PersonEntity:
          Name:
            NameFull: Tsvetkova O
      – PersonEntity:
          Name:
            NameFull: Abt ER
      – PersonEntity:
          Name:
            NameFull: Rosen L
      – PersonEntity:
          Name:
            NameFull: Kim S
      – PersonEntity:
          Name:
            NameFull: King J
      – PersonEntity:
          Name:
            NameFull: Hines OJ
      – PersonEntity:
          Name:
            NameFull: Girgis M
      – PersonEntity:
          Name:
            NameFull: Sadeghi S
      – PersonEntity:
          Name:
            NameFull: Olevsky O
      – PersonEntity:
          Name:
            NameFull: Wong D
      – PersonEntity:
          Name:
            NameFull: Yonemoto L
      – PersonEntity:
          Name:
            NameFull: Siney AM
      – PersonEntity:
          Name:
            NameFull: Kelly K
      – PersonEntity:
          Name:
            NameFull: Kivork C
      – PersonEntity:
          Name:
            NameFull: Tseng CH
      – PersonEntity:
          Name:
            NameFull: Radu CG
      – PersonEntity:
          Name:
            NameFull: Dawson DW
      – PersonEntity:
          Name:
            NameFull: Donahue TR
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 31
              M: 01
              Text: 2026 Jan 31
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2041-1723
          Numbering:
            – Type: volume
              Value: 17
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Nature communications
              Type: main
ResultId 1